Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Shanghai Jiao Tong University School of Medicine
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07486726CT.gov Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia | — | Not Yet Recruiting | — | — | — |
NCT07651176CT.gov Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy | — | Enrolling By Invitation | — | — | — |
NCT07651163CT.gov Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy | — | Enrolling By Invitation | — | — | — |
NCT06394011CT.gov Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients | — | Recruiting | — | — | — |
NCT05918198CT.gov Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia | — | Unknown | — | — | — |
NCT05659992CT.gov Clinical Study of Venetoclax Combined with CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT05264883CT.gov Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML | — | Unknown | — | — | — |
NCT04254640CT.gov Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML | — | Unknown | — | — | — |
NCT04087967CT.gov Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients | — | Unknown | — | — | — |
NCT04083911CT.gov Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60 | — | Unknown | — | — | — |
Show 4 more trialsShow fewer
NCT03045627CT.gov Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients | — | Unknown | — | — | — |
NCT02886559CT.gov Chidamide Plus DCAG for Relapsed/Refractory AML | — | Unknown | — | — | — |
NCT03181815CT.gov Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia | — | Unknown | — | — | — |
NCT02432911CT.gov Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years Old | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloid Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Aclarubicin (this asset) | Shanghai Jiao Tong University School of Medicine | P3 | B · 63 |
| Gemtuzumab | M.D. Anderson Cancer Center | P4 | A |
| Amsacrine | University Hospital, Toulouse | P4 | BBB |
| Posaconazole | AstraZeneca | P4 | BBB |
| (+)-Vincristine | Janssen Research & Development, LLC | P3 | BBB |
| Aclacinomycin | Chinese PLA General Hospital | P4 | BB |
| Alvocidib | M.D. Anderson Cancer Center | P2 | BB |
| Prednisone | Children's Oncology Group | P3 | BB |
| Therapeutic Allogeneic Lymphocytes | University of Southern California | P2 | BB |
+42 more in the Acute Myeloid Leukemia cohort
Other indications for Aclarubicin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Peripheral T-Cell Lymphoma, Not Otherwise Specified | — | P2 | CCC · 53 |
| Angioimmunoblastic T-Cell Lymphoma | — | P2 | CCC · 53 |
| ALK-Negative Anaplastic Large Cell Lymphoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Aclarubicin in Acute Myeloid Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/aclarubicin-acute-myeloid-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →